W

Wockhardt Ltd
NSE:WOCKPHARMA

Watchlist Manager
Wockhardt Ltd
NSE:WOCKPHARMA
Watchlist
Price: 1 358.9 INR 0.13% Market Closed
Market Cap: 220.8B INR

Operating Margin
Wockhardt Ltd

7.3%
Current
-0.1%
Average
6.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
7.3%
=
Operating Profit
2.2B
/
Revenue
29.8B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
IN
Wockhardt Ltd
NSE:WOCKPHARMA
220.8B INR
7%
US
Eli Lilly and Co
NYSE:LLY
985.4B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
506.1B USD
27%
CH
Roche Holding AG
SIX:ROG
252.7B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
209.2B GBP
24%
CH
Novartis AG
SIX:NOVN
206.9B CHF
33%
US
Merck & Co Inc
NYSE:MRK
246.7B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
142.4B USD
29%
No Stocks Found

Wockhardt Ltd
Glance View

Wockhardt Ltd., founded in the early 1960s, has woven its story with a blend of cutting-edge research and an unwavering commitment to healthcare. Emerging from modest beginnings as a simple pharmaceutical company in India, Wockhardt evolved into a global player. The company carved out its niche in the life sciences sector, leveraging its strength in research and development to push the boundaries of pharmaceutical innovation. Its portfolio spans an array of products including generics, biosimilars, and a focus on pioneering antibiotics that combat the growing threat of drug-resistant bacteria. Central to Wockhardt’s narrative is its significant investment in biotechnology, which fuels its innovation pipeline. By focusing on difficult-to-manufacture drugs and addressing unmet medical needs, Wockhardt not only navigates the complex pharmaceutical landscape but also establishes itself as an indispensable partner in global healthcare. Financially, Wockhardt propels its operations forward through a diverse revenue stream derived from both domestic and international markets. Its business model capitalizes on manufacturing a broad spectrum of generics that cater to the needs of emerging and developed markets alike. The company’s strategic emphasis on research-oriented endeavors is fortified by its robust infrastructure of manufacturing facilities and research centers across multiple countries. This global network enables Wockhardt to efficiently scale production and distribute its pharmaceutical creations to a wide array of markets. By securing patents and maintaining a strong focus on specialty drugs, Wockhardt effectively balances its commitments to both shareholder value and societal health obligations, illustrating a nuanced dance between business acumen and healthcare advocacy.

WOCKPHARMA Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
7.3%
=
Operating Profit
2.2B
/
Revenue
29.8B
What is the Operating Margin of Wockhardt Ltd?

Based on Wockhardt Ltd's most recent financial statements, the company has Operating Margin of 7.3%.

Back to Top